Skip to main content
Premium Trial:

Request an Annual Quote

Clovis, Strata Partner to Identify Prostate Cancer Best Responders to PARP Inhibitor

NEW YORK (GenomeWeb) — Clovis Oncology said it is working with Strata Oncology to enroll a molecularly defined subset of advanced prostate cancer patients into its late stage TRITON clinical trials program for the PARP inhibitor Rubraca (rucaparib).

Last year, the US Food and Drug Administration approved Rubraca for advanced ovarian cancer patients who have received two or more prior chemotherapies and have BRCA1/2 mutations. The agency approved the drug alongside Foundation Medicine's FoundationFocus CDxBRCA, which is a next-generation sequencing test that gauges germline and somatic BRCA mutations. 

Studies have shown that inhibition of PARP may also lead to anti-tumor effects in metastatic prostate cancer patients with mutations in BRCA1/2, ATM, and other DNA damage repair genes. Under the agreement with Clovis, Strata will refer castration-resistant prostate cancer patients with BRCA and ATM mutations for potential enrollment in Clovis' TRITON2 and TRITON 3 Rubraca studies.

As part of its own 100,000-patient observational study, Strata is providing free NGS testing to all advanced cancer patients at affiliated oncology centers and hospitals. Based on the mutations identified, Strata refers patients to ongoing clinical trials sponsored by its pharmaceutical partners.

"Through our work with Strata, we seek to address the significant challenge of identifying and enrolling the right patients … in support of advancing our precision medicine clinical trials and potentially providing rucaparib to a broader population of patients who may benefit," Clovis CEO Patrick Mahaffy said in a statement. 

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.